EP2094850A4 - PROTEIN KINASES RELATED TO CANCER - Google Patents

PROTEIN KINASES RELATED TO CANCER

Info

Publication number
EP2094850A4
EP2094850A4 EP07852282A EP07852282A EP2094850A4 EP 2094850 A4 EP2094850 A4 EP 2094850A4 EP 07852282 A EP07852282 A EP 07852282A EP 07852282 A EP07852282 A EP 07852282A EP 2094850 A4 EP2094850 A4 EP 2094850A4
Authority
EP
European Patent Office
Prior art keywords
cancer
protein kinases
kinases related
protein
kinases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP07852282A
Other languages
German (de)
French (fr)
Other versions
EP2094850A1 (en
EP2094850B1 (en
Inventor
Axel Ullrich
Jens Ruhe
Stefan Hart
Sylvia Streit
Chee Hong Wong
Boon Tin Chua
Han Kiat Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of EP2094850A1 publication Critical patent/EP2094850A1/en
Publication of EP2094850A4 publication Critical patent/EP2094850A4/en
Application granted granted Critical
Publication of EP2094850B1 publication Critical patent/EP2094850B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP07852282.8A 2006-12-01 2007-12-03 Cancer-related protein kinases Not-in-force EP2094850B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86817306P 2006-12-01 2006-12-01
PCT/SG2007/000412 WO2008066498A1 (en) 2006-12-01 2007-12-03 Cancer-related protein kinases

Publications (3)

Publication Number Publication Date
EP2094850A1 EP2094850A1 (en) 2009-09-02
EP2094850A4 true EP2094850A4 (en) 2010-08-04
EP2094850B1 EP2094850B1 (en) 2013-06-12

Family

ID=39468190

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07852282.8A Not-in-force EP2094850B1 (en) 2006-12-01 2007-12-03 Cancer-related protein kinases

Country Status (5)

Country Link
US (1) US20110008347A1 (en)
EP (1) EP2094850B1 (en)
JP (1) JP2010511382A (en)
SG (1) SG177225A1 (en)
WO (1) WO2008066498A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
WO2008089035A1 (en) * 2007-01-11 2008-07-24 Genentech, Inc. Genetic variations associated with tumors
CN101848998B (en) 2007-08-30 2016-08-03 第一三共株式会社 anti-EPHA2 antibody
WO2009087462A2 (en) * 2007-12-24 2009-07-16 Oxford Biotherapeutics Ltd. Ephrin type-a receptor 10 protein
EP2252373B1 (en) * 2008-02-05 2012-06-13 Urifer Ltd Novel fer -like protein, pharmaceutical compositions containing it and method for its use
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
EP2165710A1 (en) * 2008-09-19 2010-03-24 Institut Curie Tyrosine kinase receptor Tyro3 as a therapeutic target in the treatment of a bladder tumor
EP2169071A1 (en) * 2008-09-29 2010-03-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rodent cancer model for human FGFR4 Arg388 polymorphism
EA201990619A1 (en) 2008-10-10 2019-07-31 Амген Инк. FGF21 MUTANTS AND THEIR APPLICATION
WO2010048304A2 (en) * 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
KR20240091315A (en) 2008-11-12 2024-06-21 인리젠 Isolated renal cells and uses thereof
DK2881402T3 (en) 2009-02-12 2017-08-28 Cell Signaling Technology Inc Mutant ROS expression in human liver cancer
US20120052069A1 (en) 2009-05-05 2012-03-01 Amgen Inc Fgf21 mutants and uses thereof
SG10201402038WA (en) 2009-05-05 2014-07-30 Amgen Inc FGF21 Mutants And Uses Thereof
EP2336171A1 (en) * 2009-12-11 2011-06-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel targets for the treatment of proliferative diseases
JP2013523184A (en) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド Human FGF receptor and β-KLOTHO binding protein
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
NZ603482A (en) 2010-05-12 2014-11-28 Tengion Inc Bioactive renal cells
TW201302793A (en) 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding protein
WO2012068073A2 (en) 2010-11-15 2012-05-24 University Of Florida Research Foundation, Inc. Therapeutic and diagnostic applications targeting tnk-1
EP2646469B1 (en) 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
AU2012346540C1 (en) * 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
CN120514834A (en) 2014-03-28 2025-08-22 华盛顿大学商业中心 Breast and ovarian cancer vaccines
US11946934B2 (en) 2014-09-03 2024-04-02 Wellmarker Bio Co., Ltd. Biomarker for predicting the sensitivity to a protein kinase inhibitor and a use thereof
US9994914B2 (en) 2014-10-09 2018-06-12 Roche Molecular Systems, Inc. Mutation in the epidermal growth factor receptor kinase domain
MA43943A (en) * 2015-05-29 2018-12-12 Ignyta Inc COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH RTK MUTANT CELLS
CA3002560A1 (en) 2015-10-23 2017-04-27 Array Biopharma, Inc. 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2h)-one compounds as inhibitors of fgfr tyrosine kinases
HK1254836A1 (en) 2015-10-30 2019-07-26 Nbe-Therapeutics Ag Anti-ror1 antibodies
BR112018014615A2 (en) 2016-01-20 2018-12-11 The Scripps Research Institute ror1 antibody compositions and related methods
US11123372B2 (en) 2016-07-29 2021-09-21 Prokidney Bioactive renal cells for the treatment of chronic kidney disease
CN106480205A (en) * 2016-11-11 2017-03-08 北京吉因加科技有限公司 For detecting combined sequence and the probe of various mutations type simultaneously
EP3654952A1 (en) 2017-07-19 2020-05-27 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
SG11202000846WA (en) 2017-08-07 2020-02-27 Nbe Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
CN111225662B (en) 2017-10-17 2022-11-22 伊尼塔公司 Pharmaceutical compositions and dosage forms
US12077599B2 (en) * 2017-11-29 2024-09-03 Seoul National University R&Db Foundation, National Cancer Center Anti-ROS1 antibody and use thereof
WO2019133752A1 (en) * 2017-12-28 2019-07-04 Development Center For Biotechnology A method for predicting drug efficacy
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
EP3898626A1 (en) 2018-12-19 2021-10-27 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
US20220162572A1 (en) * 2019-03-04 2022-05-26 Tokyo Metropolitan Institute Of Medical Science NUCLEIC ACID CONSTRUCT ENCODING Trk FRAGMENT AND USE THEREOF
CN110031626A (en) * 2019-04-02 2019-07-19 浙江理工大学 A kind of marker ACK1 and its application for gastrointestinal stromal tumors migration
US12441707B2 (en) 2019-12-30 2025-10-14 Tyra Biosciences, Inc. Indazole compounds
US20230115945A1 (en) 2019-12-30 2023-04-13 Tyra Biosciences, Inc. Aminopyrimidine compounds
US12264149B2 (en) 2020-12-30 2025-04-01 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
MX2023009954A (en) 2021-02-26 2023-11-09 Tyra Biosciences Inc Aminopyrimidine compounds and methods of their use.
EP4547670A1 (en) 2022-06-29 2025-05-07 Tyra Biosciences, Inc. Polymorphic compounds and uses thereof
AU2023300362A1 (en) 2022-06-29 2025-01-09 Tyra Biosciences, Inc. Indazole compounds
WO2024138112A1 (en) 2022-12-22 2024-06-27 Tyra Biosciences, Inc. Indazole compounds
TW202535368A (en) 2023-12-15 2025-09-16 美商泰拉生物科學公司 Indazole compounds
WO2025222097A1 (en) 2024-04-19 2025-10-23 Tyra Biosciences, Inc. Indazole-based protac degraders and their anticancer activity

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343940A (en) * 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
DE3069468D1 (en) * 1979-12-19 1984-11-22 Nat Res Dev Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3611194A1 (en) * 1986-04-04 1987-10-08 Bayer Ag CANCEROSTATIC AGENT
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3920029C2 (en) * 1988-06-30 1999-05-20 Clariant Finance Bvi Ltd Dyes for coloring plastics
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
SE517975C2 (en) 2000-05-30 2002-08-13 Power Ab C Truss construction of beams composed of a three-dimensional framework and use of such truss construction
AU2002213084A1 (en) * 2000-10-11 2002-04-22 Avalon Pharmaceuticals Cancer-linked genes as targets for chemotherapy
US20050191618A1 (en) 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060194265A1 (en) * 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
AU2003225535A1 (en) * 2002-01-31 2003-09-02 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer
JP2006174701A (en) * 2003-02-24 2006-07-06 Research Association For Biotechnology Novel protein and DNA encoding the same
JP2005198640A (en) * 2003-11-25 2005-07-28 Biomarker Science:Kk Method for expressing gene

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
See also references of WO2008066498A1 *
STREIT S ET AL: "FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients", BRITISH JOURNAL OF CANCER 20060619 GB LNKD- DOI:10.1038/SJ.BJC.6603181, vol. 94, no. 12, 19 June 2006 (2006-06-19), pages 1879 - 1886, XP002577219 *
STREIT SYLVIA ET AL: "Involvement of the FGFr4 Arg388 allele in head and neck squamous cell carcinoma", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY LNKD- DOI:10.1002/IJC.20204, vol. 111, no. 2, 20 August 2004 (2004-08-20), pages 213 - 217, XP002517570, ISSN: 0020-7136, [retrieved on 20040412] *
THUSSBAS CHRISTOPH ET AL: "FGFR4 ARG388 ALLELE IS ASSOCIATED WITH RESISTANCE TO ADJUVANT THERAPY IN PRIMARY BREAST CANCER", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US LNKD- DOI:10.1200/JCO.2005.04.8587, vol. 24, no. 23, 10 August 2006 (2006-08-10), pages 3747 - 3755, XP008076988, ISSN: 0732-183X *

Also Published As

Publication number Publication date
WO2008066498A1 (en) 2008-06-05
SG177225A1 (en) 2012-01-30
US20110008347A1 (en) 2011-01-13
JP2010511382A (en) 2010-04-15
EP2094850A1 (en) 2009-09-02
EP2094850B1 (en) 2013-06-12

Similar Documents

Publication Publication Date Title
EP2094850A4 (en) PROTEIN KINASES RELATED TO CANCER
CY2019004I2 (en) MODIFIED ANTI-IL-23P19 ANTIBODIES
SI2126093T1 (en) Improving protein preparation
DK2046826T3 (en) Exendin-fusion proteins
DK3118220T3 (en) PROTEIN
EP2215246A4 (en) PROTEIN STRUCTURES
DK1999154T3 (en) MANUFACTURED HETERODIMERED PROTEIN DOMAINS
BRPI0717317A2 (en) MODULARS OF TRIAZALOPYRIDAZINE PROTEIN KINASE
SMT201500082B (en) Protein oligosaccharide conjugates
HUE038501T2 (en) Antibody preparations
EP2087096A4 (en) MODIFIED CYANOBACTERY
EP2014237A4 (en) ULTRASOUND
DK1849352T3 (en) combine
BRPI0814971A2 (en) PROTEIN
EP2092892A4 (en) ultrasonograph
DE602007012130D1 (en) MODIFIED FLAVIN-ADENINE-DINUCLEOTIDE-DEPENDENT GLUCOSE-DEHYDROGENASE
DK2035369T3 (en) THERAPEUTIC
DE602007002875D1 (en) ULTRASOUND EINSPRITZVENTIL
DE502007001779D1 (en) Towing
EP2042174A4 (en) ADHESIVE PREPARATION
DE602007003905D1 (en) Interconnects
BRPI0807858A2 (en) CANCER DISEASE MODIFICATION ANTIBODY
EP2054074A4 (en) MODIFIED ERYTHROPOIETINE
BRPI0807861A2 (en) CANCER DISEASE MODIFICATION ANTIBODY
EP2060233A4 (en) ULTRASOUND

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090629

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/28 20060101ALI20100419BHEP

Ipc: C12N 15/52 20060101AFI20080620BHEP

Ipc: C07K 16/40 20060101ALI20100419BHEP

Ipc: C07K 16/30 20060101ALI20100419BHEP

Ipc: C07K 16/00 20060101ALI20100419BHEP

Ipc: G01N 33/574 20060101ALI20100419BHEP

Ipc: C12N 15/12 20060101ALI20100419BHEP

Ipc: C07K 14/47 20060101ALI20100419BHEP

Ipc: C12N 9/00 20060101ALI20100419BHEP

Ipc: C07K 14/71 20060101ALI20100419BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100701

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HART, STEFAN

Inventor name: STREIT, SYLVIA

Inventor name: WONG, CHEE HONG

Inventor name: CHUA, BOON TIN

Inventor name: ULLRICH, AXEL

Inventor name: HO, HAN KIAT

Inventor name: RUHE, JENS

17Q First examination report despatched

Effective date: 20110318

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602007031057

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12N0015520000

Ipc: G01N0033574000

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/12 20060101ALI20120308BHEP

Ipc: G01N 33/574 20060101AFI20120308BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 616872

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007031057

Country of ref document: DE

Effective date: 20130808

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130923

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130913

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 616872

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130612

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20130612

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130912

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131014

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131012

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E018544

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

26N No opposition filed

Effective date: 20140313

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007031057

Country of ref document: DE

Effective date: 20140313

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007031057

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20131203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20131203

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20140829

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602007031057

Country of ref document: DE

Effective date: 20140701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131231

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20140701

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131231

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131203

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131203

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131231

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20131204

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130612